SR One related stories
All articles and analysis
Constellation Pharmaceuticals Closes on $15MConstellation Pharmaceuticals has raised $15 million in an extension to its Series B round, the company announced Monday. Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life Science Ventures – all existing shareholders – participated in the round. The latest infusion will help Constellation move its products toward clinical development. The company develops small molecule therapeutics for the treatment of cancer, inflammatory and immunologic disorders and other diseases.
- SpringLeaf Therapeutics Seals $15M
SpringLeaf Therapeutics has closed $15 million in a Series B financing led by new investor SR One, the venture capital arm of GlaxoSmithKline, with participation from existing shareholders Flybridge Capital Partners and North Bridge Venture Partners. SR One partner Brian Gallagher will join SpringLeaf’s board as a result. SpringLeaf is based in Boston.
- F-star Seals $21.7M in Fresh Capital
Vienna-based biopharma company f-star GmbH has raised 15 million euro ($21.7 million) in a new financing round led by SR One, the corporate venture capital arm of GlaxoSmithKline. Existing shareholder Atlas Venture, Aescap Venture, Novo Ventures, TVM Capital, Merck Serono Ventures and MP Healthcare Venture Management also participated in the round. As a result, SR One Partner Dr Deborah Harland and Dr Axel Polack of TVM Capital will join f-star's Supervisory Board.
- Genocea Biosciences Inks $35M Series B
Vaccine developer Genocea Biosciences Inc. has raised $35 million in a second round of financing. New investors Johnson & Johnson Development Corporation, Skyline Ventures and MP Healthcare Venture Management contributed to the Series B round. Existing shareholders Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners and Morningside Ventures also participated. The financing will help support clinical development of the company’s therapeutic vaccine for herpes simplex virus type 2 infections. Genocea is based in Cambridge, Mass.
- Dicerna Pharmaceuticals Gets $4M More In Series B Round’s Second Close
Dicerna Pharmaceuticals Inc. held a second close of its Series B financing round with $4 million more. The Watertown, Mass-based drug developer has raised a total of $29 million in the round. GlaxoSmithKline’s corporate healthcare venture capital arm (SR One) is a new investor. Dicerna’s existing investors include Oxford Bioscience Partners, Skyline Ventures, Abingworth and Domain Associates. Brian M. Gallagher, a partner at SR One, will join Dicerna’s board.
- Week in deals, Sept. 13, 2010
Summary of tech companies and other startups in North America that raised venture financing in the past week
- iPierian Inc. Closes Series B Equity Financing Round At $28 Million
iPierian Inc., a South San Francisco, Calif.-based biopharmaceutical company, closed its Series B equity financing at $28 million. GlaxoSmithKline’s healthcare venture capital arm SR One, Biogen Idec New Ventures and other investors participated in this closing. Existing investors (Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital, Google Ventures, FinTech Global Capital, Mitsubishi UFJ Capital and ATEL Ventures) also participated.
- peHUB Wire: Wednesday, September 8, 2010
Editor’s Note: Today’s guest column comes from Randy Schwimmer of mid-market lender Churchill Financial.
- peHUB Wire: Wednesday, September 8, 2010
Editor’s Note: Today’s guest column comes from Randy Schwimmer of mid-market lender Churchill Financial.
- Constellation Pharma Adds Onto Series B Round
Constellation Pharmaceuticals Inc., a Cambridge, Mass.-based developer of drugs that target selective regulators of epigenetic function, has raised $4.8 million in additional Series B funding led by S.R. One Ltd. The round is now closed at $22 million, including a $17.2 million first close announced last summer. Other backers include Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock. The company has raised a total of $54 million.